Baxter International (1BAX) Stock Overview
Through its subsidiaries, provides a portfolio of healthcare products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
1BAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.70 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$14.50 |
| Beta | 0.61 |
| 1 Month Change | 19.76% |
| 3 Month Change | 49.93% |
| 1 Year Change | 17.53% |
| 3 Year Change | -43.60% |
| 5 Year Change | -64.42% |
| Change since IPO | -69.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1BAX | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | 14.3% | 4.7% | 0.7% |
| 1Y | 17.5% | -8.0% | 25.9% |
Return vs Industry: 1BAX exceeded the Italian Medical Equipment industry which returned -10% over the past year.
Return vs Market: 1BAX underperformed the Italian Market which returned 23.1% over the past year.
Price Volatility
| 1BAX volatility | |
|---|---|
| 1BAX Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in IT Market | 8.0% |
| 10% least volatile stocks in IT Market | 2.9% |
Stable Share Price: 1BAX's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1BAX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 37,500 | Andrew Hider | www.baxter.com |
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories.
Baxter International Inc. Fundamentals Summary
| 1BAX fundamental statistics | |
|---|---|
| Market cap | €11.99b |
| Earnings (TTM) | -€839.16m |
| Revenue (TTM) | €9.94b |
Is 1BAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1BAX income statement (TTM) | |
|---|---|
| Revenue | US$11.47b |
| Cost of Revenue | US$7.38b |
| Gross Profit | US$4.09b |
| Other Expenses | US$5.06b |
| Earnings | -US$968.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | 35.65% |
| Net Profit Margin | -8.44% |
| Debt/Equity Ratio | 157.3% |
How did 1BAX perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 13:45 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Baxter International Inc. is covered by 34 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Matthew Taylor | Barclays |
| Matthew Miksic | Barclays |